Summary

The global peptide synthesis market is projected to surpass USD 1.41 billion in 2029 from USD 0.81 billion in 2024, with a significant CAGR of 11.7%. The peptide synthesis market is driven by several factors such as advancements in technology, increasing research in drug discovery, and the growing demand for personalized medicine. Additionally, the rising prevalence of chronic diseases such as cancer and diabetes is fueling demand for therapeutic peptides in targeted therapies further propelling the growth of the market.
“Resins and Amino acids accounted for the dominant share in the reagents market”
Based on offerings (products & services), products (Consumables and Instruments), consumables (Reagents and Other Consumables), Reagents (Resins, Amino Acids, Coupling Reagents, Dyes and Fluorescent Labelling Reagents, Deprotection Reagents, Cleavage Reagents and Other Reagents), Instruments (Peptide Synthesizers (automated and manual), Chromatography Equipment, Lyophilizers and Others). Resins form the foundation of solid-phase peptide synthesis (SPPS), serving as a stable platform for the stepwise construction of peptide chains. Advancements in resins such as preloaded resins and specialized linkers are likely to impact positively on the market.
“Peptide synthesis services dominated the market”
The services segment is further segmented into peptide library synthesis, peptide synthesis, peptide purification services, and peptide analysis services. Peptide synthesis services dominated the market due to their ability to meet the increasing demand for custom and complex peptides required in drug discovery, therapeutic development, and research applications. Additionally, the rise of personalized medicine and peptide-based vaccines has increased the demand for custom synthesis driving the segmental growth.

“Therapeutics segment dominated the application segment in 2023”
Applications segment is divided into Therapeutics, Diagnostics and Research & Development. Therapeutics by Indications (Cancer, Diabetes, Obesity, Autoimmune Disease and Other Disease Indication), Therapeutics by Molecules (Peptide-Based Vaccines, Peptide-Drug Conjugates (PDCs), Peptide Inhibitors and Other Molecules). Advancements in peptide synthesis technologies, such as solid-phase peptide synthesis (SPPS) and recombinant DNA methods, has enabled the efficient production of high-purity, cost-effective peptides for vaccine development. The growing focus on personalized immunotherapies and increased investment in peptide-based vaccine research further reinforce their leading position in the market.
“North America: the largest share of the peptide synthesis market”
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the peptide synthesis market in 2023 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the strong presence of key players like Thermo Fisher Scientific and CEM Corporation, with substantial funding for biomedical research and innovation in peptide-based therapeutics. Europe holds a significant share of the market, with countries like Germany, and UK being major contributors. This dominance attributed to strong R&D activities, collaborations between academic institutions and industry, and a growing focus on personalized medicine and peptide-based drugs.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the peptide synthesis market.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1- 45%, Tier 2- 35%, Tier 3- 20%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Bachem Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), GenScript (China), and CEM Corporation (US) are some of the major players operating in the peptide synthesis market.

Research Coverage:
This research report categorizes the peptide synthesis market offerings (products & services), products (Consumables and Instruments), consumables (Reagents and Other Consumables), Reagents (Resins, Amino Acids, Coupling Reagents, Dyes and Fluorescent Labelling Reagents, Deprotection Reagents, Cleavage Reagents and Other Reagents), Instruments (Peptide Synthesizers (automated and manual), Chromatography Equipment, Lyophilizers and Others). Services (Peptide Library Synthesis, Peptide Synthesis, Peptide Purification Services and Peptide Analysis Services), Technique (Chemical (Solid Phase Peptide Synthesis, Solution Phase peptide synthesis and Other Chemical Methods and Biological (Recombinant DNA Technology and Enzymes), Applications (Therapeutics, Diagnostics and Research & Development), Therapeutics by Indications (Cancer, Diabetes, Obesity, Autoimmune Disease and Other Disease Indication), Therapeutics by Molecules (Peptide-Based Vaccines, Peptide-Drug Conjugates (PDCs), Peptide Inhibitors and Other Molecules), End User (Pharmaceutical and biotechnology companies, CDMOs & CROs, Academic & Research Institutes, Medical Device Companies and Hospitals and Diagnostic Centers). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the peptide synthesis market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the peptide synthesis market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the peptide synthesis and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (advancements in peptide therapeutics, technological advancements,
growing use of peptides in diagnostics and research), restraints (Regulatory Hurdles, High cost of peptide synthesis and instruments), opportunities (Adoption of personalized medicine, Rise in strategic collaborations and partnerships) and Challenges (Addressing Immunogenicity, Environmental Concerns) influencing the growth of the market.
• Product/Service Development/Innovation: Detailed insights on upcoming technologies in peptide synthesis manufacturing, research and development activities, and new product/service launches in the peptide synthesis market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the peptide synthesis market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product & service offerings of leading players Thermo Fisher Scientific, Inc. (US), Bachem Holding AG (Switzerland), Kaneka Corporation (US), Inc. and Merck KGaA (Germany), among others.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 54
1.1 STUDY OBJECTIVES 54
1.2 MARKET DEFINITION 54
1.3 STUDY SCOPE 55
1.3.1 MARKETS COVERED 55
1.3.2 REGIONAL SCOPE 56
1.3.3 INCLUSIONS AND EXCLUSIONS 56
1.3.4 YEARS CONSIDERED 57
1.4 CURRENCY CONSIDERED 57
1.5 STAKEHOLDERS 57
1.6 SUMMARY OF CHANGES 58
2 RESEARCH METHODOLOGY 59
2.1 RESEARCH DATA 59
2.1.1 SECONDARY RESEARCH 60
2.1.2 PRIMARY RESEARCH 61
2.2 MARKET SIZE ESTIMATION METHODOLOGY 62
2.2.1 GLOBAL MARKET ESTIMATION 62
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 65
2.2.3 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 65
2.3 GROWTH RATE PROJECTIONS 67
2.4 DATA TRIANGULATION 69
2.5 RESEARCH ASSUMPTIONS 70
2.6 RESEARCH LIMITATIONS 71
2.7 RISK ANALYSIS 71
3 EXECUTIVE SUMMARY 72
4 PREMIUM INSIGHTS 78
4.1 PEPTIDE SYNTHESIS MARKET OVERVIEW 78
4.2 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET,
BY PRODUCT TYPE AND COUNTRY, 2023 79
4.3 PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024 VS. 2029 79
4.4 PEPTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 80

5 MARKET OVERVIEW 81
5.1 INTRODUCTION 81
5.2 MARKET DYNAMICS 81
5.2.1 DRIVERS 82
5.2.1.1 Advancements in peptide therapeutics 82
5.2.1.2 Innovations in peptide synthesis instruments 83
5.2.1.3 Growing use of peptides in diagnostics and research 83
5.2.2 RESTRAINTS 84
5.2.2.1 Regulatory hurdles 84
5.2.2.2 High cost of peptide synthesis and instruments 84
5.2.3 OPPORTUNITIES 85
5.2.3.1 Adoption of personalized medicine 85
5.2.3.2 Strategic collaborations and partnerships 85
5.2.4 CHALLENGES 86
5.2.4.1 Immunogenicity issues 86
5.2.4.2 Environmental concerns 86
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 87
5.4 PRICING ANALYSIS 87
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 88
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION 91
5.5 SUPPLY CHAIN ANALYSIS 93
5.6 VALUE CHAIN ANALYSIS 94
5.7 ECOSYSTEM ANALYSIS 97
5.7.1 PEPTIDE SYNTHESIS MARKET: PRODUCT MANUFACTURERS 97
5.7.2 PEPTIDE SYNTHESIS MARKET: SERVICE PROVIDERS 98
5.7.3 PEPTIDE SYNTHESIS MARKET: END USERS 98
5.7.4 PEPTIDE SYNTHESIS MARKET: REGULATORY BODIES 99
5.8 INVESTMENT AND FUNDING SCENARIO 99
5.9 TECHNOLOGY ANALYSIS 100
5.9.1 KEY TECHNOLOGIES 100
5.9.1.1 Solid-phase peptide synthesis (SPPS) 100
5.9.1.2 Liquid-phase peptide synthesis (LPPS) 100
5.9.1.3 Enzymatic peptide synthesis 101
5.9.1.4 Continuous-flow peptide synthesis 101
5.9.2 COMPLEMENTARY TECHNOLOGIES 101
5.9.2.1 Labeling and tracking technologies 101
5.9.2.2 Purification techniques 102
5.9.3 ADJACENT TECHNOLOGIES 102
5.9.3.1 Cell-free protein synthesis 102
5.9.3.2 Protein design and engineering 102
5.10 PATENT ANALYSIS 103
5.11 TRADE ANALYSIS 105
5.11.1 TRADE DATA FOR HS CODE 902720 (CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS) 105
5.11.1.1 Import data for HS code 902720 105
5.11.1.2 Export data for HS CODE 902720 106
5.11.2 TRADE DATA FOR HS CODE 841933 (LYOPHILISATION APPARATUS,
FREEZE DRYING UNITS AND SPRAY DRYERS) 106
5.11.2.1 Import data for HS code 841993 106
5.11.2.2 Export data for HS code 841933 107
5.12 KEY CONFERENCES AND EVENTS, 2025–2026 107
5.13 REGULATORY LANDSCAPE 108
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109
5.13.2 REGULATORY FRAMEWORK 112
5.13.2.1 North America 112
5.13.2.1.1 US 112
5.13.2.1.2 Canada 112
5.13.2.2 Europe 112
5.13.2.2.1 Germany 112
5.13.2.2.2 UK 112
5.13.2.2.3 France 112
5.13.2.3 Asia Pacific 113
5.13.2.3.1 Japan 113
5.13.2.3.2 China 113
5.13.2.4 Latin America 113
5.13.2.4.1 Brazil 113
5.13.2.5 Middle East & Africa 113
5.13.2.5.1 GCC Countries 113
5.13.2.5.2 South Africa 113
5.14 PORTER’S FIVE FORCES ANALYSIS 114
5.14.1 BARGAINING POWER OF SUPPLIERS 115
5.14.2 BARGAINING POWER OF BUYERS 115
5.14.3 THREAT OF NEW ENTRANTS 115
5.14.4 THREAT OF SUBSTITUTES 115
5.14.5 INTENSITY OF COMPETITIVE RIVALRY 116
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 116
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 116
5.15.2 BUYING CRITERIA 117
5.16 IMPACT OF AI/GENERATIVE AI ON PEPTIDE SYNTHESIS MARKET 119
5.16.1 INTRODUCTION 119
5.16.2 IMPACT OF AI ON PEPTIDE SYNTHESIS ECOSYSTEM 120
5.16.3 FUTURE OF GENERATIVE AI IN PEPTIDE SYNTHESIS ECOSYSTEM 121
6 PEPTIDE SYNTHESIS MARKET, BY OFFERING 122
6.1 INTRODUCTION 123
6.2 PRODUCTS 123
6.2.1 INCREASING ADOPTION OF SOLID AND LIQUID-PHASE PEPTIDE SYNTHESIS TO STIMULATE GROWTH 123
6.3 SERVICES 127
6.3.1 GROWING ADVANCEMENTS IN PEPTIDE DESIGN AND SYNTHESIS OPTIMIZATION TO FUEL MARKET 127
7 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE 130
7.1 INTRODUCTION 131
7.2 CONSUMABLES 131
7.2.1 REAGENTS 135
7.2.1.1 Resins 138
7.2.1.1.1 Growing demand for therapeutic peptides to boost market 138
7.2.1.2 Amino acids 141
7.2.1.2.1 Increasing advancements in synthetic amino acid modifications to aid growth 141
7.2.1.3 Coupling reagents 144
7.2.1.3.1 Rising adoption of high-throughput peptide synthesis to expedite growth 144
7.2.1.4 Dyes & fluorescent labeling reagents 147
7.2.1.4.1 Increasing demand for high-resolution, sensitive imaging technologies to promote growth 147
7.2.1.5 Deprotection reagents 150
7.2.1.5.1 Rising complexity of modified peptides and cyclic structures to facilitate growth 150
7.2.1.6 Cleavage reagents 153
7.2.1.6.1 Increasing use of complex peptides to sustain growth 153
7.2.1.7 Other reagents 156
7.2.2 OTHER CONSUMABLES 159
7.3 INSTRUMENTS 162
7.3.1 PEPTIDE SYNTHESIZERS 165
7.3.1.1 Automated peptide synthesizers 169
7.3.1.1.1 Increasing launches of automated peptide synthesizers to promote growth 169
7.3.1.2 Manual peptide synthesizers 172
7.3.1.2.1 Growing use of peptide synthesizers for early-stage drug discovery and research to fuel market 172
7.3.2 CHROMATOGRAPHY SYSTEMS 175
7.3.2.1 Increasing shift toward high-throughput and industrial-scale peptide production to amplify growth 175

7.3.3 LYOPHILIZERS 178
7.3.3.1 Rising influence of contract manufacturing organizations to encourage growth 178
7.3.4 OTHER INSTRUMENTS 181
8 PEPTIDE SYNTHESIS SERVICES MARKET, BY TYPE 185
8.1 INTRODUCTION 186
8.2 PEPTIDE SYNTHESIS 186
8.2.1 RISING ADOPTION OF PERSONALIZED MEDICINES AND TARGETED THERAPIES TO INTENSIFY GROWTH 186
8.3 PEPTIDE PURIFICATION SERVICES 190
8.3.1 GROWING EMPHASIS ON HIGH-QUALITY PEPTIDES IN PHARMACEUTICAL DEVELOPMENT AND BIOTECH TO DRIVE MARKET 190
8.4 PEPTIDE LIBRARY SYNTHESIS 193
8.4.1 INCREASING FOCUS ON SYNTHETIC BIOLOGY TO AUGMENT GROWTH 193
8.5 PEPTIDE ANALYSIS SERVICES 196
8.5.1 INCREASING ADVANCEMENTS IN MASS SPECTROMETRY AND CHROMATOGRAPHY TO BOLSTER GROWTH 196
9 PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE 200
9.1 INTRODUCTION 201
9.2 CHEMICAL METHODS 201
9.2.1 SOLID-PHASE PEPTIDE SYNTHESIS 205
9.2.1.1 Increasing use of peptides and peptide derivatives in modern medicines use to encourage growth 205
9.2.2 LIQUID-PHASE PEPTIDE SYNTHESIS 208
9.2.2.1 Growing advancements in purification technologies to boost market 208
9.2.3 OTHER CHEMICAL METHODS 211
9.3 BIOLOGICAL METHODS 215
9.3.1 RECOMBINANT DNA TECHNOLOGY 218
9.3.1.1 Increasing innovations in genetic engineering and synthetic biology to drive market 218
9.3.2 ENZYMATIC SYNTHESIS 222
9.3.2.1 Growing shift toward sustainable and eco-friendly manufacturing to propel market 222
10 PEPTIDE SYNTHESIS MARKET, BY APPLICATION 225
10.1 INTRODUCTION 226
10.2 THERAPEUTIC APPLICATIONS 226
10.2.1 THERAPEUTIC APPLICATIONS, BY INDICATION 230
10.2.1.1 Cancer 230
10.2.1.1.1 Rising clinical trials to contribute to growth 230
10.2.1.2 Diabetes 233
10.2.1.2.1 Increasing need for diabetes management to favor growth 233
10.2.1.3 Obesity 236
10.2.1.3.1 Increasing development of next-generation weight management therapies to foster growth 236
10.2.1.4 Autoimmune diseases 239
10.2.1.4.1 Growing prevalence of rheumatoid arthritis, lupus,
and multiple sclerosis to fuel market 239
10.2.1.5 Other diseases 243
10.2.2 THERAPEUTIC APPLICATIONS, BY MOLECULE 246
10.2.2.1 Peptide-based vaccines 246
10.2.2.1.1 Increasing research on infectious diseases and cancer immunotherapy to augment growth 246
10.2.2.2 Peptide-drug conjugates 250
10.2.2.2.1 Growing focus of pharmaceutical companies on drug conjugation to drive market 250
10.2.2.3 Peptide inhibitors 253
10.2.2.3.1 Rising traction for precision medicine to assist growth 253
10.2.2.4 Other molecules 257
10.3 DIAGNOSTIC APPLICATIONS 260
10.3.1 RISE OF PERSONALIZED MEDICINE AND POINT-OF-CARE TESTING TO ACCELERATE GROWTH 260
10.4 DISCOVERY & DEVELOPMENT APPLICATIONS 264
10.4.1 GROWING ADVANCEMENTS IN COMBINATORIAL CHEMISTRY AND
HIGH-THROUGHPUT PEPTIDE LIBRARIES TO DRIVE MARKET 264
11 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER 268
11.1 INTRODUCTION 269
11.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 269
11.2.1 INCREASING RESEARCH ON GENOMICS AND MOLECULAR BIOLOGY TO EXPEDITE GROWTH 269
11.3 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS 273
11.3.1 SHIFT TOWARD CUSTOM AND MODIFIED PEPTIDES TO DRIVE MARKET 273
11.4 ACADEMIC & RESEARCH INSTITUTES 276
11.4.1 INCREASING FINANCIAL AND REGULATORY SUPPORT FOR RESEARCH TO SUPPORT GROWTH 276
11.5 MEDICAL DEVICE COMPANIES 280
11.5.1 BOOMING PEPTIDE-BASED DRUG DELIVERIES TO PROMOTE GROWTH 280
11.6 HOSPITALS & DIAGNOSTIC CENTERS 283
11.6.1 RISING DEMAND FOR PEPTIDE-BASED DIAGNOSTICS TO FAVOR GROWTH 283

12 PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER 287
12.1 INTRODUCTION 288
12.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 288
12.2.1 INCREASING FOCUS ON PEPTIDE-BASED THERAPEUTICS IN ONCOLOGY AND METABOLIC DISORDERS TO INTENSIFY GROWTH 288
12.3 MEDICAL DEVICE COMPANIES 292
12.3.1 NEED TO DETECT INFECTIOUS DISEASES, CANCER, AND METABOLIC DISORDERS TO AID GROWTH 292
12.4 HOSPITALS & DIAGNOSTIC CENTERS 295
12.4.1 RISING USE OF PEPTIDE BIOMARKERS TO SUPPORT GROWTH 295
12.5 ACADEMIC & RESEARCH INSTITUTES 299
12.5.1 GROWING FOCUS ON DRUG DESIGN, VACCINE DEVELOPMENT,
AND CANCER RESEARCH TO BOOST MARKET 299
12.6 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS 302
12.6.1 INCREASING DEMAND FOR COST-EFFECTIVE PEPTIDE SYNTHESIS SERVICES TO FACILITATE GROWTH 302
13 PEPTIDE SYNTHESIS MARKET, BY REGION 306
13.1 INTRODUCTION 307
13.2 NORTH AMERICA 307
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 308
13.2.2 US 314
13.2.2.1 Well-developed healthcare and research infrastructure to aid growth 314
13.2.3 CANADA 320
13.2.3.1 Increasing government funding for advanced drugs to amplify growth 320
13.3 EUROPE 326
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 327
13.3.2 GERMANY 333
13.3.2.1 Germany to hold largest market share in Europe 333
13.3.3 UK 339
13.3.3.1 Increasing peptide synthesis research to contribute to growth 339
13.3.4 FRANCE 345
13.3.4.1 Favorable government initiatives to augment growth 345
13.3.5 ITALY 351
13.3.5.1 Growing public and private sector investments to propel market 351
13.3.6 SPAIN 357
13.3.6.1 Rising focus on advanced therapies to expedite growth 357
13.3.7 REST OF EUROPE 363

13.4 ASIA PACIFIC 369
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 370
13.4.2 CHINA 377
13.4.2.1 Expanding biopharma sector to advance growth 377
13.4.3 JAPAN 384
13.4.3.1 Growing geriatric population to fuel market 384
13.4.4 INDIA 390
13.4.4.1 Increasing investments and developments in biotechnology to favor growth 390
13.4.5 SOUTH KOREA 395
13.4.5.1 Booming biotechnology sector to amplify growth 395
13.4.6 AUSTRALIA 402
13.4.6.1 Increasing government funding and initiatives to augment growth 402
13.4.7 REST OF ASIA PACIFIC 407
13.5 LATIN AMERICA 413
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 414
13.5.2 BRAZIL 420
13.5.2.1 Growing interest in peptide-based drugs to fuel market 420
13.5.3 MEXICO 426
13.5.3.1 Increasing initiatives for stem cell research and regenerative medicine projects to foster growth 426
13.5.4 REST OF LATIN AMERICA 432
13.6 MIDDLE EAST 438
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 438
13.6.2 GCC COUNTRIES 445
13.6.2.1 Saudi Arabia 450
13.6.2.1.1 Increasing government-backed investments for infrastructure to aid growth 450
13.6.2.2 UAE 456
13.6.2.2.1 High prevalence of diabetes and cardiovascular diseases to augment growth 456
13.6.2.3 Rest of GCC Countries 462
13.6.3 REST OF MIDDLE EAST 469
13.7 AFRICA 475
13.7.1 INCREASING INVESTMENTS IN PHARMACEUTICAL INFRASTRUCTURE AND LIFE SCIENCE INNOVATIONS TO BOOST MARKET 475
13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 475

14 COMPETITIVE LANDSCAPE 482
14.1 OVERVIEW 482
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2025 482
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PEPTIDE SYNTHESIS MARKET 483
14.3 REVENUE ANALYSIS, 2019–2023 484
14.4 MARKET SHARE ANALYSIS, 2023 485
14.5 COMPANY VALUATION AND FINANCIAL METRICS 487
14.5.1 COMPANY VALUATION 487
14.5.2 FINANCIAL METRICS 487
14.6 BRAND/PRODUCT COMPARISON 488
14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 489
14.7.1 STARS 489
14.7.2 EMERGING LEADERS 489
14.7.3 PERVASIVE PLAYERS 489
14.7.4 PARTICIPANTS 489
14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 491
14.7.5.1 Company footprint 491
14.7.5.2 Region footprint 492
14.7.5.3 Offering footprint 493
14.7.5.4 Technique footprint 494
14.7.5.5 Application footprint 495
14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 496
14.8.1 PROGRESSIVE COMPANIES 496
14.8.2 RESPONSIVE COMPANIES 496
14.8.3 DYNAMIC COMPANIES 496
14.8.4 STARTING BLOCKS 496
14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 498
14.8.5.1 Detailed list of key startups/SMEs 498
14.8.5.2 Competitive benchmarking of startups/SMEs 499
14.9 COMPETITIVE SCENARIO 500
14.9.1 PRODUCT LAUNCHES 500
14.9.2 DEALS 501
14.9.3 EXPANSIONS 502

15 COMPANY PROFILES 503
15.1 KEY PLAYERS 503
15.1.1 THERMO FISHER SCIENTIFIC INC. 503
15.1.1.1 Business overview 503
15.1.1.2 Products/Services offered 505
15.1.1.3 Recent developments 506
15.1.1.3.1 Product launches 506
15.1.1.4 MnM view 506
15.1.1.4.1 Key strengths 506
15.1.1.4.2 Strategic choices 506
15.1.1.4.3 Weaknesses and competitive threats 506
15.1.2 MERCK KGAA 507
15.1.2.1 Business overview 507
15.1.2.2 Products/Services offered 508
15.1.2.3 MnM view 511
15.1.2.3.1 Key strengths 511
15.1.2.3.2 Strategic choices 511
15.1.2.3.3 Weaknesses and competitive threats 511
15.1.3 AGILENT TECHNOLOGIES, INC. 512
15.1.3.1 Business overview 512
15.1.3.2 Products/Services offered 513
15.1.3.3 MnM view 514
15.1.3.3.1 Key strengths 514
15.1.3.3.2 Strategic choices 514
15.1.3.3.3 Weaknesses and competitive threats 514
15.1.4 GENSCRIPT 515
15.1.4.1 Business overview 515
15.1.4.2 Products/Services offered 516
15.1.4.3 Recent developments 517
15.1.4.3.1 Expansions 517
15.1.4.4 MnM view 517
15.1.4.4.1 Key strengths 517
15.1.4.4.2 Strategic choices 517
15.1.4.4.3 Weaknesses and competitive threats 518
15.1.5 KANEKA CORPORATION 519
15.1.5.1 Business overview 519
15.1.5.2 Products/Services offered 520
15.1.5.3 Recent developments 521
15.1.5.3.1 Expansions 521

15.1.5.4 MnM view 521
15.1.5.4.1 Key strengths 521
15.1.5.4.2 Strategic choices 521
15.1.5.4.3 Weaknesses and competitive threats 521
15.1.6 BACHEM 522
15.1.6.1 Business overview 522
15.1.6.2 Products/Services offered 523
15.1.6.3 Recent developments 524
15.1.6.3.1 Deals 524
15.1.7 SYNGENE INTERNATIONAL LIMITED 525
15.1.7.1 Business overview 525
15.1.7.2 Products/Services offered 526
15.1.8 MESA LABS, INC. 527
15.1.8.1 Business overview 527
15.1.8.2 Products/Services offered 528
15.1.8.3 Recent developments 529
15.1.8.3.1 Product launches 529
15.1.8.3.2 Deals 529
15.1.9 BIOTAGE 530
15.1.9.1 Business overview 530
15.1.9.2 Products/Services offered 532
15.1.10 CEM CORPORATION 533
15.1.10.1 Business overview 533
15.1.10.2 Products/Services offered 533
15.1.10.3 Recent developments 534
15.1.10.3.1 Product launches 534
15.1.10.3.2 Deals 534
15.1.11 DALTON PHARMA SERVICES 535
15.1.11.1 Business overview 535
15.1.11.2 Products/Services offered 535
15.1.12 BIO-SYNTHESIS INC. 536
15.1.12.1 Business overview 536
15.1.12.2 Products/Services offered 537
15.1.13 CSBIO 538
15.1.13.1 Business overview 538
15.1.13.2 Products/Services offered 538
15.1.14 PROTEOGENIX 539
15.1.14.1 Business overview 539
15.1.14.2 Products/Services offered 539

15.1.15 INNOVAGEN AB 540
15.1.15.1 Business overview 540
15.1.15.2 Products/Services offered 540
15.1.16 BIOSYNTH 541
15.1.16.1 Business overview 541
15.1.16.2 Products/Services offered 541
15.1.16.2.1 Deals 542
15.2 OTHER PLAYERS 543
15.2.1 AURIGENE PHARMACEUTICAL SERVICES LTD. 543
15.2.2 CORDENPHARMA 544
15.2.3 JPT PEPTIDE TECHNOLOGIES 545
15.2.4 PUROLITE 546
15.2.5 BIOMATIK 547
15.2.6 CPC SCIENTIFIC INC. 548
15.2.7 ADVANCED CHEMTECH, INC. 549
15.2.8 AMBIOPHARM INC. 550
15.2.9 LUXEMBOURG BIO TECHNOLOGIES 551
15.2.10 AAPPTEC 552
15.2.11 ANYGEN 553
15.2.12 CHEMPEP 554
15.2.13 PROTEOGENIX 555
16 APPENDIX 556
16.1 DISCUSSION GUIDE 556
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 560
16.3 CUSTOMIZATION OPTIONS 562
16.4 RELATED REPORTS 562
16.5 AUTHOR DETAILS 563